Lumentum (NASDAQ:LITE | LITE Price Prediction) currently trades at $932.47, while Wall Street’s average analyst price target sits at $1,125.93. That leaves the stock priced roughly 20.8% below where the Street thinks it should be.
Lumentum makes optical and photonic components for AI data centers, including transceivers, lasers, and optical circuit switches that hyperscalers use to move traffic between GPU clusters. Wall Street is focused on the company’s position in the 800G and 1.6T transceiver ramp and management’s recent quarter, which reset the growth trajectory.
The gap matters because it opened despite that beat. Even after a sharp two-week bounce, the stock trades below where it changed hands three months ago, and a well-regarded semiconductor analyst sees more room to run.
A 90-Day Slide That Survived a Blowout Quarter
Lumentum peaked at a 52-week high of $1,085.68 and unwound through the summer, bottoming near $752 in mid-July before staging a comeback. Peak to trough, that is a drawdown north of 30%.
The selloff was largely valuation-driven. Lumentum trades at a trailing P/E of 143 and a forward P/E of 43, inviting profit-taking when hyperscaler capex chatter cools or export-control headlines flare. Management disclosed risks including product mix fluctuations, ASP declines, manufacturing capacity constraints, and tariff exposure.
Q4 revenue came in at $1.01 billion, up 109.3% year over year, with non-GAAP EPS of $3.23 beating the $2.97 consensus. Shares jumped 13.63% on the earnings report, yet the stock remains underwater versus its early May level of $973.10.
Mizuho’s $1,140 Call and Street Alignment
Mizuho’s Vijay Rakesh raised his 12-month target to $1,140 from $1,100 with an Outperform rating, implying roughly 22% upside. His thesis rests on sustained 800G and 1.6T EML transceiver demand, an OCS segment expected to clear $100 million in the September quarter alone, persistent supply-demand imbalance preserving pricing power, and beat-and-raise execution.
The broader Street is aligned. Of analysts covering Lumentum, 5 rate it Strong Buy, 16 Buy, 4 Hold, and none Sell. Recent actions skew toward reiterations and target hikes rather than downgrades, with consensus target of $1,125.93 close to Mizuho’s number.
Key catalysts are management’s Q1 FY27 guide of $1.225 billion to $1.275 billion in revenue and $4.05 to $4.35 in non-GAAP EPS, plus delivery on the multi-hundred-million-dollar CPO order slated for H1 2027. CEO Michael Hurlston said the company is “reaching our target model more than a quarter ahead of schedule.”
Lumentum Against Coherent, Fabrinet, and Ciena
Coherent (NASDAQ:COHR) trades at $355.64, up 92.69% year to date, against a consensus target of $394.62, implying roughly 11% upside with 17 Buy-equivalent ratings, 5 Holds, and no Sells. Coherent is the closest analog, and the Street sees less remaining room.
Fabrinet (NYSE:FN) sits at $571.88, up 25.61% YTD, versus a target of $732.44, or about 28% implied upside. Coverage tilts bullish at 7 Buys and 2 Holds.
Ciena (NYSE:CIEN) trades at $432.05, up 84.74% YTD, against a $565.71 target for about 31% upside. Ratings split 13 Buy, 6 Hold, and 1 Sell, with the loudest bull case in the group.
Ciena carries the largest analyst-implied upside, Fabrinet is next, and Lumentum sits in the middle at around 21%. The Street sees a real setup in Lumentum, just not the most extreme one in optical networking.
Current Valuation and Ratings
Lumentum trades at $932.47 against a consensus target of $1,125.93, an implied upside of roughly 20.8% across 25 covering analysts. Analyst targets carry uncertainty, and recent revisions have trended upward.
Ratings breakdown:
- Strong Buy: 5
- Buy: 16
- Hold: 4
- Sell: 0
Lumentum is up 152.98% year to date and 21.39% over the last month, while the S&P 500 is up 13.28% YTD. The AI optical trade has been explosive, and Lumentum is one of its most volatile expressions.
The Case For and Against
The bull case holds if you believe the OCS and 1.6T ramp shows up in September-quarter revenue as modeled, and hyperscaler capex holds through 2027. Management guiding to a $1.25 billion midpoint a quarter ahead signals real bookings, and the CPO order deliverable in H1 2027 provides a visible catalyst.
The bear case centers on concerns about ASP normalization, capacity bottlenecks, and a forward P/E of 43 that leaves no cushion. A single missed quarter on gross margin or slower OCS ramp could send the stock back toward July lows, and recent insider activity has tilted toward selling.
The setup has favored patient accumulation on pullbacks over chasing rallies at $932. With zero Sell ratings and a Street target north of $1,100, the risk/reward tilts up.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks